Crinetics reports Q4 EPS ($1.29), consensus ($1.37)

Reports Q4 revenue $6.16M, consensus $4.74M. “2025 was a breakout year for Crinetics (CRNX), as the approval and launch of Palsonify demonstrated our ability to bring an innovative therapy from concept to the patients who need it most,” said Scott Struthers, founder and chief executive officer of Crinetics. “With strong launch dynamics, we are now focused on building a business capable of scaling that success. We have the commercial infrastructure, the pipeline depth and the capital to build a premier, multi-product company that will define the future of endocrinology.”